Palvella director awarded 3,000 stock options

Palvella Therapeutics director Todd C. Davis received a new stock option grant.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Palvella Therapeutics director Todd C. Davis received a new stock option grant. He was awarded options to buy 3,000 shares of common stock at an exercise price of $102.19 per share, expiring on June 10, 2036. The options vest on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, subject to his continued service.

Insider Trade Summary

Grant/Award: 3,000 shares

Grant/Award 1 txn

Insider Davis Todd C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 3,000 contracts (Direct)

Footnotes (1)

F1. The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Options granted: 3,000 options Exercise price: $102.19 per share Underlying shares: 3,000 shares +2 more

5 metrics

Options granted 3,000 options Stock Option (Right to Buy) granted on 2026-06-10

Exercise price $102.19 per share Conversion/exercise price of stock option

Underlying shares 3,000 shares Common stock underlying the option grant

Expiration date June 10, 2036 Option expiration for this grant

Total options after grant 3,000 options Total derivative holdings from this award following transaction

Key Terms

Stock Option (Right to Buy), grant/award acquisition, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 102.1900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-10T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Todd C. Davis report in his Form 4 for PVLA?

Todd C. Davis reported receiving a grant of stock options for 3,000 shares of Palvella Therapeutics common stock. These options are a compensation award and do not represent an open-market purchase or sale of existing shares.

What is the exercise price of the new PVLA stock options granted to Todd C. Davis?

The stock options granted to Todd C. Davis have an exercise price of $102.19 per share. This is the fixed price at which he may buy Palvella Therapeutics common stock if and when the options vest and are exercised.

When do Todd C. Davis’s new PVLA stock options vest?

The options vest upon the earlier of the first anniversary of the grant date or Palvella Therapeutics’ next annual meeting of stockholders. Vesting is conditional on Todd C. Davis continuing to serve through the applicable vesting date.

How many PVLA shares are covered by Todd C. Davis’s new stock option grant?

The grant covers options to purchase 3,000 shares of Palvella Therapeutics common stock. After this grant, his total reported derivative holdings from this award are 3,000 options linked to 3,000 underlying common shares.

Do the reported PVLA option grants involve any stock sales by Todd C. Davis?

No, the Form 4 shows only a grant of stock options classified as an acquisition. There are no reported open-market sales or purchases of Palvella Therapeutics common stock in this filing, just a compensation-related award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/12/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Todd C

(Last)

(First)

(Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$102.19	06/10/2026		A		3,000		⁽¹⁾	06/10/2036	Common Stock	3,000	$0	3,000	D

Explanation of Responses:

1. The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR